ANCHOR LEAD: DRUG ELUTING STENTS ARE ONCE AGAIN IN THE NEWS, ELIZABETH TRACEY REPORTS
Drug eluting stents were back in the media limelight in a recent issue of the New England Journal of Medicine. Rick Lange, chief of clinical cardiology at Johns Hopkins, summarizes the research findings.
LANGE: The major recommendation coming out of the FDA is that patients who receive drug eluting stents should be on antiplatelet therapy for a prolonged period of time. We previously recommended that individuals take it for at least three to six months, but it looks like now they should take it for at least twelve months, and in my opinion, probably lifelong. :17
Cardiologists and the FDA now have new recommendations.
LANGE: The initial results with drug eluting stents looked very favorable, but over the long term, that is, following people for two and three years after the placement of a stent, it appears they’re associated with an increased incidence of a clot occurring in the stent, which is fatal in 20-45% of individuals. :16
So if you’ve had a drug eluting stent placed talk with your doctor about which anticlotting medicines you should take. I’m Elizabeth Tracey reporting.